Janssen, “Partnership with Hanmi is still strong, and it’s only suspended, not terminated”
“Hanmi Pharm and Janssen’s partnership is still strong, and we hope to continue the clinical trial as soon as possible,” Janssen which owns the license of HM12525A, a Hanmi Pharm’s obesity and diabetes treatment, announced through a pharmaceutical medium, Endpoints News, on the 8th(Korean time).
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
